Molecular Partners (MOLN) Stock Forecast, Price Target & Predictions
MOLN Stock Forecast
Molecular Partners stock forecast is as follows: an average price target of $29.00 (represents a 455.56% upside from MOLN’s last price of $5.22) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MOLN Price Target
MOLN Analyst Ratings
Buy
Molecular Partners Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 27, 2022 | Leerink Partners | $29.00 | $13.89 | 108.78% | 455.56% |
Molecular Partners Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $5.22 | $5.22 | $5.22 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Apr 27, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Apr 27, 2022 | Credit Suisse | Neutral | Downgrade |
Molecular Partners Financial Forecast
Molecular Partners Revenue Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | $3.05M | $2.69M | $2.34M | $11.75M | $172.78M | $1.77M | $3.53M | $3.21M | $815.00K | $2.34M | $2.34M |
Avg Forecast | $201.62K | $349.06K | $795.75K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
High Forecast | $201.62K | $349.06K | $795.96K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
Low Forecast | $201.62K | $349.06K | $795.53K | $2.70M | $380.83K | $1.40M | $1.60M | $1.65M | $4.17M | $3.27M | $11.72M | $165.59M | $14.01M | $2.03M | $2.02M | $3.73M | $13.61M | $13.33M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | 1.85% | 0.65% | 0.71% | 1.00% | 1.04% | 0.13% | 1.73% | 1.59% | 0.22% | 0.17% | 0.18% |
Forecast
Molecular Partners EBITDA Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | $-13.61M | $-13.72M | $-13.86M | $-5.56M | $153.26M | $-15.12M | $-12.18M | $-15.60M | $-17.86M | $-15.48M | $-15.48M |
Avg Forecast | $-135.59K | $-234.74K | $-535.13K | $-1.82M | $-256.10K | $-938.89K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
High Forecast | $-135.59K | $-234.74K | $-534.99K | $-1.82M | $-256.10K | $-938.89K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
Low Forecast | $-135.59K | $-234.74K | $-535.28K | $-1.82M | $-256.10K | $-938.89K | $-1.08M | $-1.11M | $-2.81M | $-2.20M | $-7.89M | $-111.48M | $-9.43M | $-1.37M | $-1.36M | $-2.51M | $-9.17M | $-8.98M |
Surprise % | - | - | - | - | - | - | - | 12.28% | 4.89% | 6.29% | 0.70% | -1.37% | 1.60% | 8.89% | 11.49% | 7.12% | 1.69% | 1.72% |
Forecast
Molecular Partners Net Income Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | $-15.32M | $-19.91M | $-11.95M | $-2.67M | $153.13M | $-17.91M | $-11.69M | $-17.63M | $-14.41M | $-15.69M | $-15.69M |
Avg Forecast | $-12.63M | $-17.54M | $39.90M | $47.38M | $-28.71M | $42.24M | $35.46M | $43.42M | $-20.13M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
High Forecast | $-12.63M | $-17.54M | $39.90M | $47.38M | $-28.71M | $42.24M | $35.46M | $43.42M | $-20.13M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
Low Forecast | $-12.63M | $-17.54M | $39.90M | $47.38M | $-28.71M | $42.24M | $35.46M | $43.42M | $-20.13M | $-21.44M | $-20.84M | $-20.14M | $-18.90M | $-18.56M | $-19.07M | $-24.74M | - | - |
Surprise % | - | - | - | - | - | - | - | -0.35% | 0.99% | 0.56% | 0.13% | -7.60% | 0.95% | 0.63% | 0.92% | 0.58% | - | - |
Forecast
Molecular Partners SG&A Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | $5.44M | $5.03M | $5.56M | $5.48M | $5.76M | $4.59M | $4.69M | $4.29M | $3.34M | $2.77M | $2.77M |
Avg Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
High Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
Low Forecast | $260.16K | $450.43K | $1.03M | $3.48M | $491.42K | $1.80M | $2.07M | $2.13M | $5.39M | $4.22M | $15.12M | $213.67M | $18.08M | $2.62M | $2.60M | $4.81M | $17.57M | $17.20M |
Surprise % | - | - | - | - | - | - | - | 2.56% | 0.93% | 1.32% | 0.36% | 0.03% | 0.25% | 1.79% | 1.65% | 0.70% | 0.16% | 0.16% |
Forecast
Molecular Partners EPS Forecast
Quarter
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | $-0.47 | $-0.61 | $-0.37 | $-0.08 | $4.74 | $-0.55 | $-0.36 | $-0.55 | $-0.49 | $-0.63 | $-0.63 |
Avg Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
High Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
Low Forecast | $-0.38 | $-0.53 | $1.20 | $1.43 | $-0.86 | $1.27 | $1.07 | $1.31 | $-0.61 | $-0.65 | $-0.63 | $-0.61 | $-0.57 | $-0.56 | $-0.57 | $-0.75 | - | - |
Surprise % | - | - | - | - | - | - | - | -0.36% | 1.01% | 0.57% | 0.13% | -7.81% | 0.97% | 0.64% | 0.96% | 0.66% | - | - |
Forecast
Molecular Partners Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
VIGL | Vigil Neuroscience | $1.73 | $11.00 | 535.84% | Buy |
MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
OPT | Opthea | $3.27 | $14.00 | 328.13% | Buy |
PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
TRDA | Entrada Therapeutics | $18.45 | $20.00 | 8.40% | Buy |